AVROBIO to sell HSC gene therapy programme to Novartis for $87.5m
Switzerland-based Novartis will pay AVROBIO $87.5m in cash at closing as compensation for the sale and transfer of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 May 23
Switzerland-based Novartis will pay AVROBIO $87.5m in cash at closing as compensation for the sale and transfer of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 May 23
The facility is expected to allow Singapore’s science and technology sector to accelerate the research, development and manufacturing…
22 May 23
According to the terms of the contract, Croda will purchase a licence from Amyris to market, distribute, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 May 23
The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by…
19 May 23
Roche in the Middle East has reaffirmed its commitment to diversity and inclusion by signing the Middle East…
18 May 23
In the Phase 2 study, which met its primary and secondary endpoints, Roche’s investigational, potent and highly selective…
18 May 23
The task force has already set up two working groups, which will focus on childhood/young adult cancer and…
18 May 23
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and…
17 May 23
Astellas and Sony will jointly develop and optimise a new ADC platform using KIRAVIA Backbone as a linker,…
17 May 23
The partnership will combine Scribe Therapeutics’ CRISPR by Design approach with Prevail Therapeutics’ expertise in genetic medicines development…